Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Carboplatin 75Paclitaxel 68Bevacizumab 44Taxes 22Cyclophosphamide 21pembrolizumab 19Gemcitabine 19Cisplatin 18Topotecan 17Hyperthermic Intraperitoneal Chemotherapy 14olaparib 13liposomal doxorubicin 13Immunoglobulin G 13Disulfides 13Specimen Handling 11Drug Therapy 11niraparib 10Cytoreduction Surgical Procedures 10Magnetic Resonance Spectroscopy 9sargramostim 7Surveys and Questionnaires 7Doxorubicin 7Docetaxel 7durvalumab 6Platinum 6Nivolumab 6Letrozole 6Granulocyte-Macrophage Colony-Stimulating Factor 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fallopian Tube Neoplasms × senaparib × Clear all
NCT06617923 2025-10-27

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
18 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡